Literature DB >> 23504063

Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers.

Tuya Pal1, Susan Vadaparampil, Jongphil Kim, Yan Xu, Sue Friedman, Steven A Narod, Kelly Metcalfe.   

Abstract

Although men and women are equally likely to carry a mutation in the BRCA1 and BRCA2 (BRCA) genes, the clinical significance of mutations in men remains incompletely defined. We sought evaluate interest of individuals from BRCA families to participate in a research study focused on men from BRCA families. Through an anonymous survey posted on the website of the BRCA patient advocacy organization, facing our risk of cancer empowered (FORCE), data was collected over a 21 month period (August 2010-June 2012) from members of BRCA families. The survey was completed by 405 individuals with known BRCA mutations, including 150 males and 232 females. The median age of survey respondents was 49 years (50 years for males and 48 years for females). Overall, 84% of survey respondents indicated prior BRCA mutation testing (95.2% females, 67.3% males). For the overall group of survey respondents, 84% (86% females, 84% males) indicated they would tell their male relatives about a research study focused on high risk men from BRCA families, and 53% (39% females, 74% males) thought that their male relatives would be interested in participating in such a study. Despite limited studies focused on men from BRCA mutation positive families, our survey suggests that both male and female family members are highly interested in focused on male BRCA mutation carriers. The importance of further studying this topic is underscored by emerging literature that suggest cancer surveillance and treatment decisions may improve outcomes in men with BRCA mutations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504063      PMCID: PMC4521628          DOI: 10.1007/s10689-013-9624-0

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  26 in total

1.  Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.

Authors:  Heather Thorne; Amber J Willems; Eveline Niedermayr; Ivan M Y Hoh; Jason Li; David Clouston; Gillian Mitchell; Stephen Fox; John L Hopper; Damien Bolton
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

2.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Authors:  R Moslehi; W Chu; B Karlan; D Fishman; H Risch; A Fields; D Smotkin; Y Ben-David; J Rosenblatt; D Russo; P Schwartz; N Tung; E Warner; B Rosen; J Friedman; J S Brunet; S A Narod
Journal:  Am J Hum Genet       Date:  2000-03-16       Impact factor: 11.025

3.  BRCA1/2 genetic testing uptake and psychosocial outcomes in men.

Authors:  Kristi D Graves; Rhoda Gatammah; Beth N Peshkin; Ayelet Krieger; Christy Gell; Heiddis B Valdimarsdottir; Marc D Schwartz
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

4.  Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.

Authors:  Josephine Wagner Costalas; Mark Itzen; John Malick; James S Babb; Betsy Bove; Andrew K Godwin; Mary B Daly
Journal:  Am J Med Genet C Semin Med Genet       Date:  2003-05-15       Impact factor: 3.908

5.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

6.  Experiences of genetic risk: disclosure and the gendering of responsibility.

Authors:  L d'Agincourt-Canning
Journal:  Bioethics       Date:  2001-06       Impact factor: 1.898

7.  Predictive testing for BRCA1 and 2 mutations: a male contribution.

Authors:  P A Daly; C Nolan; A Green; W Ormiston; N Cody; T McDevitt; B O'hIci; D Byrne; E McDermott; D N Carney; N O'Higgins; D E Barton
Journal:  Ann Oncol       Date:  2003-04       Impact factor: 32.976

8.  To tell or not to tell: barriers and facilitators in family communication about genetic risk.

Authors:  K Forrest; S A Simpson; B J Wilson; E R van Teijlingen; L McKee; N Haites; E Matthews
Journal:  Clin Genet       Date:  2003-10       Impact factor: 4.438

9.  Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Authors:  S M Edwards; D G R Evans; Q Hope; A R Norman; Y Barbachano; S Bullock; Z Kote-Jarai; J Meitz; A Falconer; P Osin; C Fisher; M Guy; S G Jhavar; A L Hall; L T O'Brien; B N Gehr-Swain; R A Wilkinson; M S Forrest; D P Dearnaley; A T Ardern-Jones; E C Page; D F Easton; R A Eeles
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

10.  Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.

Authors:  Alexander Liede; Imtiaz A Malik; Zeba Aziz; Patricia de los Rios Pd; Elaine Kwan; Steven A Narod
Journal:  Am J Hum Genet       Date:  2002-08-13       Impact factor: 11.025

View more
  2 in total

1.  Male Oncology Research and Education program for men at high risk for prostate cancer.

Authors:  J Lorentz; S K Liu; D Vesprini
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

2.  Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.

Authors:  Go Woon Jeong; Wonkyo Shin; Dong Ock Lee; Sang-Soo Seo; Sokbom Kang; Sang-Yoon Park; Myong Cheol Lim
Journal:  Cancer Res Treat       Date:  2020-08-11       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.